Oligomers Are Promising Targets for Drug Development in the Treatment of Proteinopathies
Currently, there is no effective treatment of proteinopathies, as well as their diagnosis in the early stages of the disease until the first clinical symptoms appear. The proposed model of fibrillation of the Aβ peptide and its fragments not only describes molecular rearrangements, but also offers m...
Main Author: | Oxana V. Galzitskaya |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-01-01
|
Series: | Frontiers in Molecular Neuroscience |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fnmol.2019.00319/full |
Similar Items
-
Exploring Amyloidogenicity of Peptides From Ribosomal S1 Protein to Develop Novel AMPs
by: Oxana V. Galzitskaya, et al.
Published: (2021-08-01) -
The Toxicity and Polymorphism of β-Amyloid Oligomers
by: Ya-ru Huang, et al.
Published: (2020-06-01) -
Bioinformatics Analysis of Actin Molecules: Why Quantity Does Not Translate Into Quality?
by: Anna V. Glyakina, et al.
Published: (2020-12-01) -
Toxic species in amyloid disorders: Oligomers or mature fibrils
by: Meenakshi Verma, et al.
Published: (2015-01-01) -
Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model
by: Fernando Goñi, et al.
Published: (2018-01-01)